劲方医药-B(02595)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02595 劲方医药-B

休市中 09-25 16:08:14

29.900

-0.180

-0.60%

最高30.420	最低29.160	成交量59.76万
今开30.080	昨收30.080	日振幅4.19%
总市值114.52亿	流通市值104.95亿	总股本3.83亿
成交额1,774万	换手率0.17%	流通股本3.51亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02595","market":"HK","secType":"STK","nameCN":"劲方医药-B","latestPrice":29.9,"timestamp":1790323694007,"preClose":30.08,"halted":0,"volume":597600,"delay":0,"changeRate":-0.005984042553191481,"floatShares":351000000,"shares":383000000,"eps":-6.07,"marketStatus":"休市中","change":-0.18,"latestTime":"09-25 16:08:14","open":30.08,"high":30.42,"low":29.16,"amount":17735816,"amplitude":0.041888,"askPrice":29.9,"askSize":2000,"bidPrice":29.8,"bidSize":124000,"shortable":3,"etf":0,"ttmEps":-3.946,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1790559000000},"marketStatusCode":7,"adr":0,"listingDate":1758211200000,"exchange":"SEHK","adjPreClose":30.08,"openAndCloseTimeList":[[1790299800000,1790308800000],[1790312400000,1790323200000]],"volumeRatio":0.0527713777376876,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02595","defaultTab":"news","newsList":[{"id":"1151961390","title":"劲方医药-B（02595）披露董事会及三大专门委员会最新成员构成","url":"https://stock-news.laohu8.com/highlight/detail?id=1151961390","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1151961390?lang=zh_cn&edition=full","pubTime":"2026-09-24 17:01","pubTimestamp":1790240464,"startTime":"0","endTime":"0","summary":"2026年9月24日，劲方医药科技（上海）股份有限公司在香港发布公告，公布董事会及其下设三大专门委员会的成员名单。公司董事会由七名董事组成，包括三名执行董事、 一名非执行董事及三名独立非执行董事。公告显示，此次披露的董事会及专门委员会组成结构符合相关监管要求，为公司治理提供组织保障。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187561501","title":"劲方医药-B（02595）宣布非执行董事陶莎辞任","url":"https://stock-news.laohu8.com/highlight/detail?id=1187561501","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1187561501?lang=zh_cn&edition=full","pubTime":"2026-09-24 16:35","pubTimestamp":1790238947,"startTime":"0","endTime":"0","summary":"劲方医药科技（上海）股份有限公司（股票代码：02595，简称“劲方医药-B”）9月24日公布，因个人工作事务，非执行董事陶莎已辞任，自2026年9月24日起生效。\\n\\n公司表示，陶莎确认其与董事会无意见分歧，亦无其他需提请香港联合交易所有限公司或公司股东注意的事项。\\n\\n截至本公告日期，劲方医药-B董事会成员构成为：执行董事吕强、兰炯及张巍；非执行董事朱竞阳；独立非执行董事卢韶华、周德敏及李波。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669463525","title":"劲方医药-B(02595)：陶莎辞任非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2669463525","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669463525?lang=zh_cn&edition=full","pubTime":"2026-09-24 16:33","pubTimestamp":1790238802,"startTime":"0","endTime":"0","summary":"智通财经APP讯，劲方医药-B(02595)发布公告，陶莎女士(陶女士)因个人工作事务，已辞任非执行董事，自2026年9月24日起生效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1500438.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09939","BK1574","159938","BK1161","02595","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669378874","title":"劲方医药-B(02595)转仓市值总计9.12亿港元 占比9.11% 从中国证券登记结算香港转出2458.84万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2669378874","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669378874?lang=zh_cn&edition=full","pubTime":"2026-09-24 08:19","pubTimestamp":1790209186,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，9月23日，劲方医药-B出现仓位异动，转仓市值总计9.12亿港元，占比9.11%。该公司股东向中国国际金融香港证券转入878.2万股，从中国证券登记结算香港转出2458.84万股。该临床项目于2026年8月13日申请，公示截止日期为2026年9月24日。公司原计划根据市场惯例，于该临床项目正式纳入BTD名单后公告。但根据《上市规则》相关条文 ，特于现阶段公告此项拟纳入BTD名单的审评进展。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1500234.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","161027","09939","159938","02595","BK1574","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669717909","title":"劲方医药-B盘中涨超9% GFH375联合西妥昔单抗联合疗法拟纳入突破性疗法认定名单","url":"https://stock-news.laohu8.com/highlight/detail?id=2669717909","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669717909?lang=zh_cn&edition=full","pubTime":"2026-09-23 10:22","pubTimestamp":1790130154,"startTime":"0","endTime":"0","summary":"劲方医药-B盘中涨超9%，截至目前，股价上涨5.97%，现报30.16港元，成交额5506.69万港元。公司临床项目GFH375联合西妥昔单抗联合疗法，于2026年9月18日被国家药品监督管理局药品审评中心拟纳入突破性疗法认定名单，治疗既往经奥沙利铂、氟尿嘧啶类和伊立替康为基础的化疗失败的KRAS G12D突变型转移性结直肠癌。公司原计划根据市场惯例，于该临床项目正式纳入BTD名单后公告。但根据《上市规则》相关条文 ，特于现阶段公告此项拟纳入BTD名单的审评进展。","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2026/09/23102258519698.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1574","02595","09939","159938","BK1515","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669176281","title":"港股异动 | 劲方医药-B(02595.HK)早盘涨超7% GFH375联合西妥昔单抗联合疗法拟纳入突破性疗法认定名单","url":"https://stock-news.laohu8.com/highlight/detail?id=2669176281","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669176281?lang=zh_cn&edition=full","pubTime":"2026-09-23 09:33","pubTimestamp":1790127229,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1515","09939","BK1161","BK1574","02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669173802","title":"劲方医药-B(02595)公布关于GFH375、GFH276相关临床研究数据的发布安排","url":"https://stock-news.laohu8.com/highlight/detail?id=2669173802","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669173802?lang=zh_cn&edition=full","pubTime":"2026-09-23 08:06","pubTimestamp":1790122007,"startTime":"0","endTime":"0","summary":"智通财经APP讯，劲方医药-B 发布公告，公司将于2026年10月15日举行线上投资者交流会，公布在研产品 GFH375联合西妥昔单抗治疗 KRAS G12D 突变实体瘤的初步研究数据。公司将于2026年10月25日举行线上投资者交流会，进一步解读 GFH276 现场口头报告数据。于2023年12月，Verastem 选择 GFH375/VS7375 作为其合作的领头项目，并于2025年1月对 GFH375 获得许可 、乃该合作框架内诞生的第一个许可。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1499618.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","BK1161","02595","BK1574","09939","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669194666","title":"港股公告掘金 | 英硅智能：达成一项合约价值最高达数千万美元的AI联合开发合作，构建并商业化生物学基础模型","url":"https://stock-news.laohu8.com/highlight/detail?id=2669194666","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669194666?lang=zh_cn&edition=full","pubTime":"2026-09-22 09:00","pubTimestamp":1790038849,"startTime":"0","endTime":"0","summary":"重大事项：欢创科技(06802)拟全球发售1158.88万股 预计9月30日上市纳真科技(09856)：香港公开发售获35.16倍认购 每股发售价32.96港元劲方医药-B(02595)：股价近日有所上升，临床项目GFH375联合西妥昔单抗联合疗法拟纳入突破性疗法认定名单翰思艾泰-B(03378)与晶泰科技签署战略合作框架协议及XtalPi Science技术平台使用授权协议顺丰控股(06936)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1499101.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["QTOC","VXUS","BK1155","BK1151","AIPO","06936","LU2213484517.USD","BK1518","VTHR","02595","03696","BK1161","BK4588","01911","ARTY","AGIX","BK1586","BK1526","BK1141","BK1147","BK1589","00354","CHAT","KCAI","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669293199","title":"劲方医药-B(02595.HK)：股价近日有所上升，临床项目GFH375联合西妥昔单抗联合疗法拟纳入突破性疗法认定名单","url":"https://stock-news.laohu8.com/highlight/detail?id=2669293199","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669293199?lang=zh_cn&edition=full","pubTime":"2026-09-22 08:11","pubTimestamp":1790035894,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","09939","BK1574","BK1515","02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177056817","title":"劲方医药-B（02595）GFH375联合西妥昔单抗治疗方案拟纳入国家药监局突破性疗法认定","url":"https://stock-news.laohu8.com/highlight/detail?id=1177056817","media":"公告速递","labels":["policyRegulatory","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1177056817?lang=zh_cn&edition=full","pubTime":"2026-09-22 08:05","pubTimestamp":1790035550,"startTime":"0","endTime":"0","summary":"劲方医药科技（上海）股份有限公司9月22日发布公告称，其临床项目GFH375联合西妥昔单抗联合疗法已于2026年9月18日被国家药品监督管理局药品审评中心拟纳入突破性疗法认定名单，适应症为治疗既往经奥沙利铂、氟尿嘧啶类和伊立替康为基础的化疗失败的KRAS G12D突变型转移性结直肠癌。根据香港联交所证券上市规则第18A.05条的警示声明，公司无法保证GFH375能够成功开发或最终上市销售。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669133491","title":"劲方医药-B(02595)：截至9月18日共回购87.2万股H股","url":"https://stock-news.laohu8.com/highlight/detail?id=2669133491","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669133491?lang=zh_cn&edition=full","pubTime":"2026-09-21 08:25","pubTimestamp":1789950354,"startTime":"0","endTime":"0","summary":"智通财经APP讯，劲方医药-B(02595)发布公告，截至2026年9月18日，公司于香港联合交易所有限公司进行一系列H股回购，共回购87.2万股H股，约占公司截至本公告日期已发行股本总额的约0.227%。公司或将评估市场情况，继续实施其2026年H股回购计划。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1498473.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159938","09939","BK1515","02595","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669497133","title":"劲方医药-B(02595)转仓市值总计11.25亿港元 占比12.80% 从渣打银行(香港)转出4373.71万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2669497133","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669497133?lang=zh_cn&edition=full","pubTime":"2026-09-21 08:24","pubTimestamp":1789950270,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，9月18日，劲方医药-B(02595)出现仓位异动，转仓市值总计11.25亿港元，占比12.80%。该公司股东向高盛(亚洲)证券转入4444.87万股，从渣打银行(香港)转出4373.71万股。劲方医药发布公告，于2026年9月18日，该公司斥资811.9万港元回购31.9万股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1498474.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","09939","159938","02595","BK1515","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128000031","title":"劲方医药-B（02595）披露最新回购进展：已回购872,000股H股，占总股本约0.227%","url":"https://stock-news.laohu8.com/highlight/detail?id=1128000031","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1128000031?lang=zh_cn&edition=full","pubTime":"2026-09-21 08:11","pubTimestamp":1789949513,"startTime":"0","endTime":"0","summary":"2026年9月21日，劲方医药-B发布自愿性公告，更新其2026年H股回购计划的实施情况。公告显示，截至2026年9月18日，公司已通过香港联合交易所有限公司累计回购H股872,000股，约占截至公告日期已发行股本总额的0.227%。本次回购基于公司于2026年5月11日股东周年大会获授权的一般性H股回购授权。公司提醒投资者，回购行动取决于市场状况，亦不保证任何特定的回购时间表、数量或价格。投资者在买卖劲方医药-B H股时需审慎行事。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109026549","title":"劲方医药科技(上海)股份有限公司9月18日回购31.9万股，涉资约811.90万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1109026549","media":"公告速递","labels":["shareholding","buyback","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1109026549?lang=zh_cn&edition=full","pubTime":"2026-09-18 17:51","pubTimestamp":1789725098,"startTime":"0","endTime":"0","summary":"2026年9月18日，劲方医药科技(上海)股份有限公司发布翌日披露报表，披露当日于香港联合交易所场内回购31.9万股普通股，占该次回购前公司已发行股本的约0.091%。本次回购价格每股在24.80港元至26.44港元之间，总计耗资约811.90万港元。回购完成后，公司已发行股份总数调整为350,757,020股，库存股份数增至872,000股。公司确认本次股份回购已遵守香港联合交易所证券上市规则及相关法律法规，并已获得董事会正式授权。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"劲方医药科技(上海)股份有限公司9月18日回购31.9万股，涉资约811.90万港元","news_tag":"shareholding,buyback,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668967329","title":"劲方医药-B(02595)9月17日斥资约157.38万港元回购6.3万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2668967329","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668967329?lang=zh_cn&edition=full","pubTime":"2026-09-17 20:49","pubTimestamp":1789649376,"startTime":"0","endTime":"0","summary":"智通财经APP讯，劲方医药-B(02595)发布公告，于2026年9月17日该公司斥资约157.38万港元回购6.3万股，回购价格为每股24.78至25.1港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1497614.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","BK1161","BK1574","09939","159938","02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156832081","title":"劲方医药-B 9月17日回购63,000股，耗资约157.38万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1156832081","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1156832081?lang=zh_cn&edition=full","pubTime":"2026-09-17 20:46","pubTimestamp":1789649160,"startTime":"0","endTime":"0","summary":"劲方医药科技（上海）股份有限公司于2026年9月17日发布公告，披露近期在香港联合交易所场内回购公司H股事宜。根据公告，劲方医药-B在当日回购63,000股H股股份，占该公司回购前已发行股份总数约0.018%。是次回购每股价格介乎港币24.78元至港币25.10元，成交量加权平均每股回购价为港币24.9815元，总涉资约157.38万港元。股份回购完成后，公司已发行股份总数由351,139,020股减少至351,076,020股，同时公司持有的库藏股数量增至553,000股。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"劲方医药-B 9月17日回购63,000股，耗资约157.38万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145357704","title":"劲方医药-B：9月16日回购16.9万股，耗资约421.75万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1145357704","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1145357704?lang=zh_cn&edition=full","pubTime":"2026-09-16 18:41","pubTimestamp":1789555262,"startTime":"0","endTime":"0","summary":"劲方医药科技(上海)股份有限公司于2026年9月16日发布翌日披露报表，披露当日通过香港联交所场内回购169,000股H股股份，约占此前公司已发行股份总数的0.048%。本次回购的每股价格介乎24.78港元至25.22港元，合计支付约421.75万港元。公告披露，截至2026年9月16日收市后，公司已发行股份总数为351,139,020股，库藏股数量增至490,000股。根据公司在公告中的信息，上述回购行为符合香港联交所证券上市规则及相关法律法规。该公告由公司联席公司秘书张巍签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"劲方医药-B：9月16日回购16.9万股，耗资约421.75万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667602715","title":"劲方医药-B(02595)9月16日斥资约421.75万港元回购16.9万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2667602715","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667602715?lang=zh_cn&edition=full","pubTime":"2026-09-16 18:32","pubTimestamp":1789554778,"startTime":"0","endTime":"0","summary":"智通财经APP讯，劲方医药-B(02595)发布公告，于2026年9月16日该公司斥资约421.75万港元回购16.9万股，回购价格为每股24.78至25.22港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1496928.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","09939","02595","BK1161","159938","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146097775","title":"劲方医药-B2026年中期营收42.47百万元","url":"https://stock-news.laohu8.com/highlight/detail?id=1146097775","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1146097775?lang=zh_cn&edition=full","pubTime":"2026-09-16 16:37","pubTimestamp":1789547821,"startTime":"0","endTime":"0","summary":"劲方医药-B披露2026年中期业绩，报告期内实现营收42.47百万元，同比上一年同期的88.74百万元下降约52%。报告期内公司毛利约22.74百万元，而上一年度同期为71.82百万元，毛利率从约80.96%下降至约53.51%。经营活动使用的现金流量净额为283.68百万元，上年同期该项数值约为50.49百万元。分业务来看，知识产权许可收入由上年同期的82.88百万元降至报告期内的11.71百万元，主要是知识产权授权收入减少，部分被药物供货收入大幅增加所抵消。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"劲方医药-B2026年中期营收42.47百万元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667281675","title":"【券商聚焦】交银国际维持劲方医药（02595）买入评级 指临床催化剂丰富","url":"https://stock-news.laohu8.com/highlight/detail?id=2667281675","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667281675?lang=zh_cn&edition=full","pubTime":"2026-09-16 09:28","pubTimestamp":1789522097,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际研报指，劲方医药-B 上半年许可收入同比有所减少，但药物供应收入同比大增567%。GFH375治疗2L+ KRAS G12D突变NSCLC的II期初步结果：1）疗效：中位随访11个月时，mPFS为8.3个月、mOS尚未达到、12个月OS率达到77%。与RMC-9805的I期结果相比，GFH375在治疗线数更靠后、过往用药历史相似的患者中取得了相似的mPFS，整体12个月OS率、ORR、DCR也好于后者或基本一致。目前，公司正在中国开展一项同适应症的III期研究，并已获得CDE突破性疗法认定。","market":"other","thumbnail":"https://static.szfiu.com/news/20250106/ODRhMzI4MWM5YTc2MTY1NjgxNGQwMTEwODUwOTcyNzQ0Mg==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/ODRhMzI4MWM5YTc2MTY1NjgxNGQwMTEwODUwOTcyNzQ0Mg==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1991711","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159938","09939","KCE","02595"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.genfleet.com","stockEarnings":[{"period":"1week","weight":0.1544},{"period":"1month","weight":-0.0754},{"period":"3month","weight":0.2305},{"period":"6month","weight":-0.0834},{"period":"1year","weight":-0.2529},{"period":"ytd","weight":0.2574}],"compareEarnings":[{"period":"1week","weight":-0.0097},{"period":"1month","weight":-0.0446},{"period":"3month","weight":0.0811},{"period":"6month","weight":-0.0177},{"period":"1year","weight":-0.0746},{"period":"ytd","weight":-0.0437}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"劲方医药科技（上海）有限公司是一家专注于创新药物研发的中国公司。该公司为肿瘤、自身免疫性疾病和炎症性疾病提供有效的新型治疗方案。该公司的研发平台涵盖靶点发现、分子发现与评估、转化科学和临床开发，以及制剂研究、工艺开发和质量分析等关键化学生产和控制环节。该公司主要致力于新分子类型和新药物模式的开发，分子工艺路线和质量标准的研究，以及差异化临床开发策略和路径的探索。该公司主要在中国国内和海外市场开展业务。","exchange":"SEHK","name":"劲方医药-B","nameEN":"GENFLEET-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"劲方医药-B(02595)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供劲方医药-B(02595)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"劲方医药-B,02595,劲方医药-B股票,劲方医药-B股票老虎,劲方医药-B股票老虎国际,劲方医药-B行情,劲方医药-B股票行情,劲方医药-B股价,劲方医药-B股市,劲方医药-B股票价格,劲方医药-B股票交易,劲方医药-B股票购买,劲方医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"劲方医药-B(02595)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供劲方医药-B(02595)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}